Cite
HARVARD Citation
Komaki, Y. et al. (2018). Meta‐Analysis of the Risk of Immune‐Related Adverse Events With Anticytotoxic T‐Lymphocyte‐Associated Antigen 4 and Antiprogrammed Death 1 Therapies. Clinical pharmacology & therapeutics. 103 (2), pp. 318-331. [Online].